Disappointing Alzheimer’s drug trial results send VTV Therapeutics shares plunging

VTV Therapeutics Inc. saw its stock price fall by more than 65 percent in after-market trading Monday after it disclosed disappointing results from the clinical trial of an experimental Alzheimer’s medication. The High Point-based company announced that the Phase 3 clinical trial assessing the effects of the drug Azeliragon in patients with mild Alzheimer’s disease failed to achieve either co-primary endpoint.Shares of VTV Therapeutics plunged 65 percent to $1.14, down $2.12 per share, in after-hours trading as of 6:15 p.m.VTv Therapeutics announced the company will terminate all current clinical trials of azeliragon, which included two separate Phase 3 trials each with about 400 participants per trial.
Read the Full Story at www.wraltechwire.com